Abbott Laboratories ABT recently received a new FDA approval with its Proclaim XR spinal cord stimulation system (SCS) for people with chronic pain. This time the regulatory body has approved an ...

(RTTNews) - Abbott (ABT) said that the U.S. Food and Drug Administration has approved new expanded magnetic resonance imaging or MRI compatibility for its Proclaim XR Spinal Cord Stimulation (SCS) ...

It was originally approved in 2019 for the treatment of chronic pain. The Food and Drug Administration (FDA) has approved the Proclaim™ XR spinal cord stimulation (SCS) system for the treatment of ...

The new indication for Abbott's Proclaim™ XR SCS system provides a non-medication option for people with painful diabetic peripheral neuropathy Spinal cord stimulation is proven to be more effective ...

The US Food and Drug Administration (FDA) has approved updated labeling that expands MRI compatibility for Abbot’s Proclaim XR spinal cord stimulation (SCS) system, the company announced. The FDA ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved the Proclaim XR spinal cord stimulation system to treat painful diabetic peripheral ...

DUBLIN, Dec. 9, 2019 /PRNewswire/ -- The "Global Spinal Cord Stimulation (SCS) Market: Size, Trends & Forecasts (2019-2023)" report has been added to ResearchAndMarkets.com's offering. Global Spinal ...

ST. PAUL, Minn.--(BUSINESS WIRE)--St. Jude Medical, Inc. (NYSE:STJ), a global medical device company and an international leader in chronic pain therapy development, today announced FDA approval of ...

ST. PAUL, Minn.--(BUSINESS WIRE)--St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced U.S. Food and Drug Administration approval for full-body magnetic resonance (MR) ...